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The clinical effectiveness of many drugs depends upon the accurate 
control of drug concentration levels in the blood plasma. Unfortunately, sev-
eral factors make it difficult to target and maintain optimal drug concentra-
tion levels. These factors include variability in physiological parameters, 
drug interactions, and measurement and sample errors. The presence and 
nature of these variables complicates the application of rational drug therapy. 
In this thesis special emphasis is placed on two important aspects of 
drug administration. These areas are the instruction of pharmacological 
principles in drug kinetics and the application of modern control techniques 
to drug dosing. 
Purpose of Research 
The purpose and final product of this thesis is the creation of a software 
teaching tool that can be used to illustrate and experiment with issues in the 
administration of drugs. The software and text of the thesis is specifically ori-
ented to providing information about the kinetics and variability that occur 
in the administration of the drug theophylline. The development of a simu-
lation tool for experimentation with issues in administration of theophylline 
is important because theophylline has a limited therapeutic range that re-
quires the accurate maintenance of drug plasma concentrations (between ap-
1 
proximately 10 to 20 | ig/ml). Drug levels that are above 20 | ig /ml frequently 
result in toxic side effects and drug levels that are below 10 | ig /ml have re-
duced therapeutic effectiveness. 
To accomplish the goals of this thesis, various types of information and 
modeling techniques have been combined. These techniques include control 
methods, fuzzy logic, and pharmacological concepts and principles. 
Required Information, Techniques, and Methods 
Pharmacokinetics 
Successful drug therapy requires the consideration of many factors. 
These factors include the selection of an appropriate form and the design of 
an optimal schedule for administering the drug. The selection of these factors 
requires an understanding of the kinetics of drug absorption, distribution, and 
elimination. Pharmacokinetics is the study of these factors and their relation-
ships. 
Fuzzy Logic Modeling Techniques 
Fuzzy logic is used to incorporate aspects of human knowledge into the 
program's software algorithms. Fuzzy logic is based on the mathematical 
concept of the fuzzy set and was proposed by Lofti A. Zadeh in 1965 [1]. 
Fuzzy logic provides a convenient way to express the relationships of objects, 
and facilitates the representation of complex input output relationships. It 




The incorporation of information about the patient with expert rules 
requires a robust control algorithm. Two types of control algorithms are 
demonstrated in this thesis. They are Fuzzy Associative Memory Rule 
Controller (FAM) and Discrete Sliding Mode Control. The FAM based con-
troller is based on rules from medical documentation and practitioner inter-
views, and the implementation of discrete sliding mode control builds upon 
the work of Godwin [2]. 
Thesis Topics and Scope 
The first section of the thesis, consisting of chapters 2 and 3, is devoted 
to the explanation of pharmacological principles and to the development of a 
mathematical model for theophylline kinetics. Chapter 2 presents important 
principles of drug pharmacokinetics and chapter 3 develops the model that is 
used in the software to represent theophylline kinetics. 
The second section of the thesis explains how fuzzy sets can be used to 
model practitioner experience and presents information on the software tool 
that was developed to accompany this thesis. Chapter 4 provides a review of 
fuzzy logic modeling and develops a framework for combining patient in-
formation and expert rules with modern control techniques. In chapter 5, 
Information about the software program and features is provided and infor-
mation about the simulation examples for dose dumping, drug interactions, 
and capsule release rates is provided. Simulation results for the drug admin-
istration controllers that are implemented in the software are shown in chap-
ter 6 and recommendations are made for the future development of these 




Before developing and presenting the pharmacokinetic model used in 
this thesis, a review of some of the underlying factors that determine and 
govern drug pharmacokinetics is needed. To help in this endeavor, the fol-
lowing chapter focuses on presenting the principles and concepts that are 
necessary for understanding the distribution and movement of drugs in the 
human body. Figure 2.1 shows the interrelationship that exists between the 
three most important stages of drug kinetics - the absorption, distribution, 
and elimination steps. 
The absorption step is the process by which a drug enters the blood 
plasma of the body. Distribution is the transport of drug molecules from the 
blood region of the body into the surrounding tissues and organs, and elimi-
nation is the removal of drug from the body. An important process that af-
fects each of the three steps is the process of transporting drug molecules 














Figure 2.1 Drug Kinetics in the Human Body. 
In the following section, factors that affect drug transport are presented. 
After reviewing these concepts, information about the absorption, distribu-
tion, and elimination steps are presented. Although the material in this 
chapter is applicable to many drugs, special emphasis has be given to theo-
phylline. This information will be used in chapter 3 to develop a mathemati-
cal model of theophylline kinetics for use in the computer simulation pro-
gram. 
Drug Transport 
Drug transport is the movement of drug molecules throughout organ 
and tissue membranes and is crucial to the drug absorption, distribution, and 
elimination phases. Drug transport behavior can be quite complex, because 
drugs frequently cross several different membranes and spaces [3]. In order to 
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simplify the modeling process, drug transport will be modeled at the macro-
scopic level. Modeling at the macroscopic level permits multiple paths to be 
lumped together so that only the total transport behavior is observed. For 
those familiar with heat transfer analysis, this technique is similar to the way 
engineer's combine resistances to obtain heat transfer coefficients. When us-
ing lumped modeling techniques, the individuality of each sub-process is lost, 
but the overall behavior is, hopefully, preserved. This functional simplifica-
tion holds true as long as the sub-processes are relatively invariant or main-
tain counterbalancing effects in the presence of other changes to the system. 
The pharmacological concepts of drug transport that are important to 
understanding issues in drug kinetics are permeability, perfusion, saturation, 
protein binding, passive diffusion, facilitated diffusion, and active transport. 
Permeability 
Permeability represents the resistance that drug molecules encounter 
when penetrating the cellular membranes in tissues and organs. Several dif-
ferent factors influence the permeability of cellular tissues to drug molecules. 
Of these factors, three are frequently mentioned as determinants to perme-
ability. They are lipid solubility, the degree of ionization, and the molecular 
weight [4]. The importance of these factors on the kinetics of a drug can be 
illustrated by considering the degree of ionization. 
The degree of ionization is defined as the ratio of drug in the ionized 
and nonionized state. Since drugs are believed to be transferred primarily in 
their un-ionized form, a drug's degree of ionization can alter drug permeabil-
ity and affect drug absorption, transport, and elimination [5]. For example, 
changes in the intestinal pH can affect the permeability of some drugs across 
intestinal tissues and alter drug absorption. Fortunately, theophylline, which 
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is a weak acid, has pKa of 9. Using the following relation for weak acids, it can 
be shown that theophylline is relatively unionized over the range of 1.0 to 8.0 
pH typically found in the gastrointestinal tract, and it's permeability due to 
ionization is, therefore, not likely to be sensitive to changes in pH. 
„ , (nonionized acid) ,_ „. 
pKa = pH + log . —— (2.1) 
(ionized acid) 
Perfusion 
Perfusion is a measure of how well blood is circulated or perfused 
through tissues and organs. It is typically expressed in the units of milliliters 
of blood per minute per volume of tissue. Values range from 10 for lungs to 
0.025 for resting muscle or fat [6]. The rate of transport across membranes can 
be rate-limited by either perfusion or permeability. As drug permeability de-
creases, perfusion becomes less significant in determining the transport rate 
of drugs and membrane permeability becomes the rate-limiting step. 
Saturation 
Saturation is a system non-linearity that frequently manifests itself as 
an upper limit to the rate at which physical processes occur. Saturation be-
havior can be observed in many aspects of drug transport and its manifesta-
tion varies from drug to drug. Quite often, saturation effects are linked to 
drug concentrations. Higher concentrations promote saturation phenomena, 
while lower concentrations are less likely to cause its effects. An example of 
absorption phase saturation has been seen in the drugs Riboflavin and 
Ascorbic Acid [7]. Before saturation, absorption rates steadily increase with 
larger doses up to a certain point. Beyond this point, larger doses have di-
7 
minishing changes in drug absorption, and eventually drug absorption can 
become relatively fixed at some maximum value. When this happens, the 
administration of larger doses in an attempt to increase drug concentration 
may be futile, because very little additional drug will reach body tissues. One 
way to reduce this type of saturation phenomenon is to give smaller doses 
more frequently. 
In addition to concentration related saturation, other factors have also 
been linked to saturation. These factors include drug interactions, intestinal 
mobility, the presence of food, diseases, and the duration of drug administra-
tion. A recent journal article [8] provides an excellent overview of the satu-
ration behavior of several drugs (including theophylline). The specifics of 
theophylline saturation will be presented in the section on elimination, be-
cause saturation phenomena for this drug are primarily seen in the elimi-
nation phase. 
Protein Binding 
Protein binding is a measure of how a drug binds with proteins in the 
body and can be expressed by the following relationship: 
Drug + Protein <=> Drug-Protein Complex (2.2) 
The degree of protein binding is typically expressed by the percentage or frac-
tion unbound and is defined by the following relation: 
fu = Cu/C (2.3) 
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In the case of theophylline and many other drugs, it is the unbound concen-
tration (Cu) that is usually important. This is because only the unbound drug 
can diffuse or be transported into tissues and sites of action [9,10]. As a result, 
protein binding frequently plays an important role in both the distribution 
and elimination phases of drug kinetics. Because plasma blood samples 
represent the total concentration of drug (C) and not the unbound concentra-
tion, samples are only good predictors of the therapeutically active unbound 
concentration if protein binding remains relatively stable. 
Passive Diffusion 
Passive diffusion is the process by which most drugs are transported 
through membranes in the body [11,12]. In passive diffusion, drug molecules 
move down a concentration gradient from areas of higher concentration to 
areas of lower concentration. This process is governed by Fick's equation: 
Rate of Diffusion = P x SA x (Cul - Cu2) (2.4) 
Where (P) is the permeability of the membrane , (SA) is the surface area , and 
(Cu) is the unbound concentration. Since only the unbound drug is available 
for transport across these membranes, the concentration difference is ex-
pressed in terms of the unbound concentration rather than the total concen-
tration. System equilibrium occurs when the difference in the unbound con-
centrations across the membrane goes to zero. Passive diffusion has the char-
acteristics that each drug molecule diffuses independently of others and that 
the system cannot be saturated [13]. 
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Facilitated Diffusion 
Facilitated diffusion is a form of carrier-mediated transport. This form 
of transport was developed partially because of the observation that some 
drugs pass through membranes at higher than expected rates and from the 
observation that these transport rates become saturated at higher concentra-
tions [14]. These transport observations suggest the existence of carriers 
which transport drug molecules across membrane surfaces. Like passive dif-
fusion, drug transport occurs in facilitated diffusion from areas of higher 
concentration to areas of lower concentration, and the equilibrium is reached 
when the difference in concentrations is zero. The process does not require 
an expenditure of energy and is not inhibited by metabolic poisons [15]. 
Facilitated diffusion can exhibit specificity, a preferential transport of certain 
types of molecular structures, and competitive inhibition. Competitive inhi-
bition is the reduction in drug transport rates that can result when different 
drugs of similar chemical structure compete for transport carriers across the 
same membrane. 
Active Transport 
Active transport is another form of carrier-mediated transport. Unlike 
facilitated diffusion, active transport is capable of moving drug molecules 
from areas of lower concentration to areas of higher concentration. As a re-
sult of this uphill transport, a release of metabolic energy is needed for active 
transport, and this process can be inhibited by metabolic poisons such as arse-
nate and fluoride [16]. Active transport exhibits saturation phenomena, 
specificity, and competitive inhibition [17]. 
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Phases of Drug Kinetics 
Absorption Phase 
For our purposes, we will investigate the administration of theo-
phylline through two administration routes. These routes are direct intra-
venous drug infusion into the blood stream and the oral administration of 
solid preparations such as capsules. When administering the drug intra-
venously, the drug is instantly available for transport to secondary tissues 
from the blood plasma. However, when administering a drug orally, an ab-
sorption phase from the gastrointestinal system will occur. 
The absorption phase of solid preparations occurs in three distinct 
steps. These are disintegration, dissolution, and absorption. During the 
disintegration step, the compressed tablet form is broken into smaller units. 
In the case of time release capsules, the outer capsule shell dissolves and re-
leases beads of coated drug material. After disintegration, dissolution of the 
drug particles begins. During this step, the drug material is diffused into the 
surrounding gastrointestinal fluid where it becomes available for the absorp-
tion step. The rate at which dissolution happens is proportional to the sur-
face area of the drug particles and the solubility of the drug. As a result, 
changes in the pH of the stomach or small intestines will alter the solubility 
of drug compounds, and may alter the rate of dissolution. Once the drug dis-
solves into the surrounding fluid, absorption occurs through either passive 
or active diffusion processes. The predominant mode of absorption for most 
drugs is reported to be by passive diffusion [18]. In the case of passive diffu-
sion, absorption is characterized by a linear dependency on the administered 
dose. In contrast, active absorption processes will frequently be linear at low 
11 
dosages, but exude saturation phenomena at higher dosages. This saturation 
phenomena is partially due to the limited availability of drug transport sites. 

















Figure 2.2 Dependency of Absorption Rates on Dosage Size 
The rate of each absorption step is dependent on individual drug char-
acteristics and complexity. One drug formulation may have an absorption 
limited step, in which case, drug transport is relatively insensitive to changes 
that affect the dissolution or disintegration phases. However, different form 
of the same drug may be dissolution rate limited. In general, added complex-
ity in the dosage form increases the number of potential rate-limiting steps 
and increases the risk for incomplete or erratic absorption. From a modeling 
and controls' standpoint, these phenomena become important, because 
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individual patient characteristics and drug forms will alter the predictability 
and controllability of a drug input to the patient body system. Figure 2.3 [20] 
demonstrates the variation in bioavailability risk as a function of dosage 
complexity. 
Absorption Rate 
Slowest >» Fastest 
Sustained Enteric Coated Tablets Capsules 
Release Coated Tablets 
Tabllets 
Bioavailability Risk 
Greatest ^ Least 
Figure 2.3 Drug Complexity and Bioavailability Risk. 
While some absorption does occur in the stomach, the larger surface 
area, higher blood flow, and lower pH of the small intestine make it the pri-
mary site for drug absorption. Changes in gastric emptying (the rate of drug 
presentation to the small intestine) and changes in intestinal mobility (the 
amount of time a drug takes to pass through the small intestine) can affect 
drug absorption rates. The significance of these changes depends on the 
dosage form and the physiological characteristics of the patient body system. 
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Absorption of Theophylline 
Theophylline is primarily administered intravenously as amino-
phylline (bioavailability « 90%). This means that if we discount losses in ad-
ministration devices, such as tubing, that 45 mg out of a 50 mg dose will be 
available for use by the body. When administering theophylline orally, a 
multiplicity of forms are available. These preparations vary in frequency of 
delivery, bioavailability, and have unique release curves as a function of 
time. Figure 2.4 [21] demonstrates the differences in absorption rates that can 
be seen with different forms of theophylline tablets. This particular graph 
compares the absorption rates of coated (slow-release) and uncoated tablets. 
1.0 












- * * * * 
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• Coated 
Note the slower absorption 
rate for coated tablets 
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1 0 1 5 
— I — 
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Time (Hours) 
Figure 2.4 Comparison of Release Rates for Coated and 
Uncoated Theophylline Tablets. 
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Oral formulations, with their complicated release mechanisms, are 
prone to complications. One such complication is called dose dumping. This 
is a phenomenon characterized by the unexpected and sudden release of 
theophylline. A complete explanation of the dose dumping phenomena is 
provided in chapter 5 as background information for the simulation example 
of dose dumping that is available as a teaching example in the software pro-
gram. 
Distribution Phase 
After the drug is absorbed or infused into the blood stream, it is avail-
able for distribution to other tissues in the body. During distribution, drug 
molecules are transported throughout the body until an equilibrium exists be-
tween the diffusible form of the drug in the tissues and the diffusible form of 
the drug in the perfusing blood is reached [22]. The determinants of drug 
distribution are not completely understood. Some factors that are known to 
affect the distribution process include permeability, perfusion, degree of ion-
ization, and protein binding. 
Extent of Distribution. The extent of distribution across membranes 
and into body tissues is determined by a number of factors and can vary sig-
nificantly from drug to drug and patient to patient. To compare the differ-
ences in distribution, a commonly used concept is the volume of distribution 
(Vd). This volume is defined by the following relationship: 
_ Amount of Drug in the body at equilibrium . 
Measured Plasma Drug Concentration 
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The volume of distribution is a measure of the apparent volume over which 
a drug is distributed and is expressed in the units of liters/Kg of body weight. 
The volume of distribution does not, however, represent the actual physical 
size of fluid or tissue volumes in the body. The volume of distribution can 




Volume = Vp 






Volume = Vt 
Amount = Vt x Ct 
Figure 2.5 2-Compartment Model for Volume of Distribution 
Using this model, the total amount of drug in the body is expressed by the fol-
lowing equation: 
Amount = Vp x Cp + Vt x Ct (2.6) 
Substituting A = Vd x Cp for the amount of drug and Kr = Ct/Cp for the ratio 
of total concentrations into (2.6) yields: 
Vd = Vp + Vt x Kr (2.7) 
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Therefore, the volume of distribution is expressed as the sum of the plasma 
volume (approximately 3 liters in adults) and the total tissue volume multi-
plied by a ratio of concentrations. Since the body is composed of many tissue 
volumes, it is more accurate to express the previous relationship as 
Vd = Vp + £ (Vtj x Kri) 
l 
(2.8) 
From this expression, it is seen that factors which alter tissue volume and/or 
the concentration ratio will also directly affect the volume of distribution. 
Two factors that can alter the extent of distribution are the degree of 
ionization and protein binding. The importance of ionization can be illus-
trated by the pH partition hypothesis [24]. According to this hypothesis, equi-
librium is reached when the un-ionized species of a drug are equal on both 
sides of the tissue membrane. Increased accumulation of the drug occurs on 
the side of the membrane that has a pH value which favors the ionized form 
of the drug. The influence of pH on weak acid drug concentrations is illus-















Figure 2.6 The pH Partition Hypothesis for a Weak Acid Drug. 
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The pH Partition Hypothesis is seen in the drugs salicylate and phenobarbital. 
Both of these drugs have a restricted access to the central nervous system 
(CNS). If the blood pH changes and becomes more acidic, the nonionized 
forms of these drugs will increase and more drug will distribute to the CNS. 
This transport phenomenon explains why reversing systemic acidemia helps 
treat toxicity, because a reduction in blood pH will facilitate the exit of these 
agents from the CNS [25]. 
The influence of protein binding on the extent of drug distribution is 
quite significant. Since only unbound drug molecules can cross membranes, 
protein binding affects the distribution of total drug concentrations in much 













Figure 2.7 Protein Binding Effects on the Extent of Distribution 
Here, protein binding causes drugs to preferentially accumulate on the side of 
the membrane that has greater protein binding (smaller fraction unbound). 
Equation 2.7 can be re-expressed to account for protein binding effects. 
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The fraction of unbound drug in the plasma is given by: 
fup = Cup/Cp (2.9) 
Similarly, the fraction of unbound drug in the tissues is given by: 
fut = Cut/Ct (2.10) 
Combining equations 2.7, 2.9, 3.0 for the equilibrium situation (at which the 
unbound concentrations are equal in both the tissues and plasma) yields: 
Vd = Vp + Vt x - ^ (2.11) 
fu t 
From this relationship, it is seen that the volume of distribution decreases 
when plasma protein binding increases a n d / o r tissue binding decreases. 
Although this model sufficiently shows the overall concepts of protein bind-
ing, Rowland and Tozer [26] have suggested that a three compartment repre-
sentation for protein binding is indicated for drugs with high levels of protein 
binding and small volumes of distribution. This is particularly important for 
drugs with volumes of distribution that are less than 0.2 l i ters/Kg. Such 
drugs include warfarin, ibuprofen, tolmetin, and acetylsalicylic acid. Since 
theophylline typically has a volume of distribution of about 0.45 liters/Kg and 
since it is moderately bound, a review of the three compartment model is 
defered to the reader. 
The potential clinical implications and importance of protein binding 
from a drug administration standpoint can be illustrated by changes that have 
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been observed in the drugs phenytoin, thiopental, and warfarin [27]. In these 
drugs, a reduction in protein binding increases the amount of unbound drug. 
Such changes in protein binding result from a variety of conditions such as 
burns, pregnancy, renal disease, and cirrhosis [28]. Here, the unbound drug 
becomes available for elimination and transport across membranes into sur-
rounding tissues. In these particular drugs, it has been found that the 
amount of free drug in the plasma after the change is almost the same as that 
before prior to the change [29]. This can present a clinical problem, because 
the measured drug level, which is based on the total drug, decreases. The 
danger in this phenomenon is that the new equilibrium total drug con-
centration could be misinterpreted as being too low. If an increase in drug 
dosage is prescribed during these conditions, toxicity can result. 
Theophylline Distribution Characteristics. The rate of theophylline 
distribution is very high. Within 30 to 60 minutes of a single bolus dose of 
theophylline, the body tissues reach a near equilibrium state with the blood 
concentrations. The rate of distribution is believed to be relatively in-
sensitive to drug interactions, disease states, and saturation effects. 
The extent of theophylline distribution can vary significantly from pa-
tient to patient. Although the average value for the volume of distribution is 
0.45 liters/Kg, values range from about 0.3 to 0.7 liters/Kg [30]. The mean 
volume of distribution for premature newborns, adults with hepatic cirrho-
sis, acidemia, and the elderly has been reported to be larger due to reduced 
plasma protein binding in these patients [31]. The change in protein binding 
is also believed to be partially responsible for a reduction in the therapeutic 
range of theophylline in premature newborns [32]. Recall that as protein 
binding decreases, the level of free and therapeutically active theophylline in-
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creases. Based on this observation, increased sensitivity to theophylline is 
anticipated in patients with other conditions that affect protein binding and 
may explain why some reports of theophylline-induced seizures in patients 
with acidosis have occurred at marginally toxic levels [33]. Burn patients 
and obese patients can also experience large changes in the volume of 
distribution. 
Elimination Phase 
Drugs are removed from the body through the process of elimination. 
There are two basic elimination mechanisms. First, drugs can be eliminated 
through excretion. In excretion, drug chemicals exit the body through paths 
such as the air that is exhaled from the lungs or the urine from the kidneys. 
Drugs can also be removed by the process of metabolism. During metabolism, 
drug chemicals are changed by biotransformation into new forms called 
metabolites. Drug metabolism can occur in various places in the body includ-
ing the skin, kidneys, and liver. Quite often, the therapeutic effects of a drug 
are caused by the metabolites that result from a drug instead of the drug itself. 
These types of drugs are called prodrugs. 
Elimination takes place in primarily two places, the liver and the kid-
neys. The liver eliminates drugs through the process of metabolism and the 
kidneys remove drugs primarily through excretion. Since theophylline is 
eliminated almost entirely by the liver, greater emphasis will be placed on ex-
plaining the elimination processes that occur in this organ. 
Clearance is a term used for measuring the effectiveness of an elimi-
nating organ. Clearance can be described in a variety of organ-specific ways. 
Some examples include hepatic clearance, renal clearance, plasma clearance, 
and blood clearance. 
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The plasma clearance (Op) is defined as the ratio of the rate of drug elimina-
tion to the total plasma drug concentration [34]: 
Plasma Clearance = Clp = Rate of Elimination/Cp (2.12) 
Another useful measure of elimination is the extraction ratio. The ex-
traction ratio is a measure of the efficiency of drug removal. The extraction 
ratio is limited to values between 0.0 and 1.0 and is defined by the following 
equation: 
E = Rate of Extraction _ Qb • (Qn - Cou t) _ (Q n - Cout) ^ _ 
Rate of Presentation Q , . Q- Q n 
Qb is the flow of blood to the organ and C is the blood concentration. The ex-
traction ratio can be used to express the blood clearance as: 
Blood Clearance = Clb = Qb • Eb (2.14) 
In order to better understand the concept of clearance and extraction ra-
tio, let's consider an example. If an organ, such as the liver, has an extraction 
ratio of 0.5 and the blood flow to that organ is 1.0 li ters/min then the organ 
completely removes all of the drug from the blood at a rate of 0.5 liters/min. 
Thus, if we ignore saturation effects and consider a blood concentration of 10 
mg/liter, the organ will remove 5 mg of drug/min. 
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Liver Elimination and Clearance. As mentioned earlier, removal of 
drug in the liver takes place primarily through metabolism. During 
metabolism, the administered drug is altered through biotransformation into 
new chemical species. These new species may be pharmacologically active or 
inactive. Since theophylline metabolizes into inactive forms, we shall only 
consider this case. 













Figure 2.8 Liver Structure and Elimination Processes 
A number of different sub-processes are involved in the elimination of drugs 
from the liver. These processes include various forms of diffusion, chemical 
reactions, transport mechanisms, etc. As is the case with other biological pro-
cesses, each individual step is a factor in determining the overall rate at 
which the process occurs. 
Drugs that have a high extraction ratio (> 0.7) are, under normal condi-
tions, insensitive to the rate at which sub-processes occur within the liver. 
Instead, liver processes occur so rapidly in these drugs, it is the blood flow to 
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the liver that limits the rate of drug removal [36]. Some examples of drugs 
with a high extraction ratio include lidocaine, morphine, and nitroglycerin. 
For drugs with a low extraction ratio, the rate of elimination is affected 
by the speed of the sub-processes that occur inside the liver. The rate of elim-
ination for these drugs are affected by such factors as: slow enzymatic reac-
tions, poor diffusion into the hepatic cell, slow diffusion of drug out of the 
blood cell, slow dissociation of the drug from plasma proteins, poor biliary 
transport, or a combination of these factors. 
Drugs that have a low extraction ratio are sensitive to changes in pro-
tein binding. This dependency occurs because only the unbound drug pene-
trates the membranes of the hepatocyte and is available for elimination. 
Therefore, the rate of drug elimination in the liver is directly related to the 
unbound concentration (Cu) of the drug in the plasma. This dependency is 
expressed by the relation: 
Rate of Elimination = Clu • Cu (2.15) 
Note that the clearance value for this expression is also based on the unbound 
drug concentration. 
In addition to protein binding sensitivity, some drugs with a low ex-
traction ratio are also sensitive to changes in enzyme activity. The elimina-
tion of these drugs is usually rate-limited by the speed of the enzymatic reac-
tions that biotransform the drug into its various metabolites. Saturation is a 
characteristic behavior of these drugs. In addition, these drugs can be affected 
by the administration of other drugs which alter either the availability of en-
zymes or the rate of the enzyme reactions. 
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Kidney Elimination and Clearance. The kidneys eliminate drugs 
through excretion. The rate of drug excretion is defined by three basic param-
eters. These parameters are the rate of filtration, the rate of secretion, and the 









Filtration occurs in the glomerulus of the kidney. Although filtration 
is always occuring, extraction by this method alone is usually rather low. 
Only the unbound drug in the plasma (Cu) is filtered by the kidneys. The 
drug that is bound to macromolecules or blood cells is unable to pass through 
the glomerular membranes [37]. The rate of filtration is expressed by the fol-
lowing relationship: 
Rate of Filtration = GFR • Cu (2.17) 
The GFR is called the glomerular filtration rate and typically averages 120 
milliliters/minute in a 70 Kg adult man. A frequently used technique for 
measuring the effectiveness of an individuals kidney filtration is to test the 
urine for the presence of creatinine. Creatinine is eliminated through the fil-
tration process. 
Secretion is an active transport process which occurs primarily in the 
proximal tubule of the kidney. Although the kidney secretion process is ac-
tive, it shows a low degree of specificity to drug structure and is able to pass a 
variety of different drugs. As with other active processes, drugs that are 
transported by the same secretion system in the kidney may compete and in-
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hibit each other's secretion rate. Kidney secretion, like liver elimination, 
shows greater dependence on protein binding for drugs with a low extraction 
ratio. These drugs are typically insensitive to changes in kidney perfusion, 
and the sum of kidney perfusion and secretion has been found to vary pro-
portionably with changes in the fraction unbound (fu). Drugs that have a 
high extraction ratio in the kidney are usually insensitive to changes that oc-
cur in protein binding. These drugs are typically perfusion rate-limited. 
Reabsorption is the third factor which affects the renal elimination of 
drugs. Reabsorption occurs primarily along the proximal tubule of the kid-
ney. The membranes in the tubule act as a barrier to water soluble substances; 
therefore, lipophilic substances tend to be highly reabsorbed and polar sub-
stances have poor reabsorption [38]. 
Reabsorption must occur if the renal clearance is less than the clear-
ance from filtration. The rate of drug reabsorption varies from almost 
complete reabsorption to almost no reabsorption. Reabsorption transport is 
primarily by passive diffusion, but active transport processes also occur. The 
reabsorption of drug molecules occurs during the reabsorption of water fil-
tered by the glomerulus of the kidney. Approximately 80 to 98% of the water 
filtered by the kidneys is reabsorbed [39]. The rate of reabsorption is sensitive 
to changes in both urine flow and urine pH. 
Drugs that are highly reabsorbed are particularly sensitive to changes in 
urine flow. One such drug is ethyl alcohol. At equilibrium, the concentra-
tion of the unbound drug in the urine is almost identical to that in the blood. 
Therefore, a change in urine flow will also alter clearance. This relationship 
is expressed as: 
Renal Clearance = fu • Urine Flow (2.18) 
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Reabsorption can also be affected by the pH of the urine. This sensitiv-
ity results because the kidney membranes act as a barrier to ionized sub-
stances. As the pH changes, the levels of ionized and non-ionized drug will 
change, and the reabsorption rate of these chemical species will also increase 
or decrease. 
Theophylline Elimination Characterisitics. The elimination of theo-
phylline takes place primarily in the liver [40,41]. In the liver, theophylline 
is transformed into relatively inactive metabolites that are excreted in the 
urine. One of these metabolites is caffeine. Although caffeine formation 
occurs in all patients, it is most significant in neonates because of its long half-
life. The metabolizing process occurs over multiple pathways by both first 
order and capacity limited processes. The hepatic extraction ratio for 
theophylline is very low and is only about 10% [42]. Except for neonates, a 
small percentage of less than 15% of the total dose of theophylline is 
eliminated in the kidneys in its unchanged form. The renal clearance of 
theophylline in neonates is significantly higher and approximately 50% of the 
dose is eliminated from the kidneys unchanged [43]. Consequently, dosage 
adjustment is not necessary during renal failure (except in neonates). 
The renal clearance of theophylline metabolites is much faster than the 
glomerular filtration rate. As a result, metabolite concentrations are much 
lower than theophylline drug concentrations. This phenomenon explains 
why the only active theophylline metabolite, 3-methylxanthine, has no 
pharmacological effect. 
The interpatient variability of theophylline clearance is extremely large 
and is likely due to variations in the rate of hepatic biotransformation. This 
suggests that theophylline elimination is rate-limited by the metabolic pro-
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cesses which occur in the liver [44]. Clearance values for theophylline have 
been shown to vary with diseases, drug interactions, age, and diet. Some re-
ports have also indicated some variations due to obesity and gender. These 
variations can be extremely large (greater than a 100%). 
Theophylline elimination also exhibits saturation. This is due to the 
capacity limitations for some metabolic processes in the liver. Two primary 
characteristics of theophylline saturation phenomena have been observed. 
These are a decrease in clearance over time, and a decrease in clearance as 
dosages are increased. The likelihood of observing theophylline saturation 
increases at higher dosages. 
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CHAPTER III 
THEOPHYLLINE KINETICS MODEL 
A model of the patient body system is needed to simulate the kinetic 
behavior of drugs in a patient. The following chapter discusses three different 
modeling approaches for developing pharmacokinetic models and presents 
the application of the compartmental approach to develop a representation 
for theophylline kinetics. Although the model presented is specifically ori-
ented to the drug theophylline, it also applicable to other drugs with similar 
kinetic and transport behavior. 
Modeling Approaches 
Model Independent Approach 
The model independent approach uses sampled data to describe the 
transient behavior of drug concentrations. In this curve-fitting approach, 
sampled data is used to determine the coefficients in the exponential series, as 
a basis for determining representative equations. In linear model indepen-
dent kinetics, a summation of exponential functions is frequently used to de-
scribe the drug kinetics [45]. For example, the following equation is an ex-
pression for the concentration after an intravenous bolus dose: 
n 
Concentration (t) = ]T Q • e ' (3.1) 
i=l 
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When using a model independent approach, care must be taken in generaliz-
ing the derived equations since errors in the sampled data or unique patient 
characteristics can skew the results. 
Compartmerttal Approach 
The compartmental modeling approach idealizes the body as a set of 
interconnected homogeneous compartments. For example, a one compart-
ment model lumps all of the body tissues into a single unit. Higher order 
models, such as two and three compartment models, break the body into 
more units. 
The number of compartments needed to represent the transient re-
sponse is determined through analysis of the sampled data. Data that displays 
mono-exponential behavior is modeled as a single compartment, data that 
displays bi-exponential behavior is modeled by two compartments, etc. 
Compartmental models segment tissues and areas of drug distribution 
into groups that represent the kinetic variability of the body as regions of slow 
and fast distribution. Although this segmentation is useful, it is still an ap-
proximation to the actual physiological system, and compartments rarely rep-
resent actual physical volumes. 
Model Dependent Approach 
In the model dependent approach, kinetic formulas and models are 
based upon the processes that define the system being modeled. The com-
plexity of the models is dependent upon the kinetics of the drug, the amount 
of information available, and the level of realism required. One advantage of 
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model-dependent approaches is the ability to incorporate physical realism 
into the model. 
Theophylline Kinetics Model 
The modeling approach adopted for the theophylline kinetics model is a 
combination of the compartmental and model dependent philosophies. This 
permits the development of a representation that is similar to the compart-
mental models presented in texts on pharmacokinetics but also maintains a 
closer connection to the physical processes than the model independent ap-
proach. 
Particular emphasis is given in developing the model to recognizing 
that the distribution, elimination, and therapeutic efficacy of theophylline are 
dependent on the unbound concentrations of the drug. Many model inde-
pendent approaches ignore this factor and, as a result, yield transport coeffi-
cients that imply active diffusion processes. This conflicts with the observa-
tion that most drug transport occurs by passive diffusion. A model that is 
based on the unbound concentrations removes this confusion and allows us 
to demonstrate the importance of protein binding on the volume of distribu-
tion, rate of elimination, and therapeutic level. 
Compartmental Representation 
Frequently, theophylline behaves kinetically like a mono-exponential 
function, and is modeled using one compartment. This single compartment 
representation is clinically accurate, but hides the presence of other variables, 
such as protein binding, that are important in drug kinetics. In order to in-
corporate these effects, a two-compartment model is used. 
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The two-compartment model that was selected segments the body into 
a volume for the blood plasma and a volume for the surrounding tissues and 
organs. This model is shown graphically on the following page in Figure 3.1. 
Note that the volume in compartment number one is a plasma volume 
rather than a blood volume, because most drug measurements are taken 
from plasma and protein binding is typically expressed in terms of the plasma 
proteins. 
ABSORPTION 









Figure 3.1 Compartmental Model for Theophylline Distribution 
In this model, absorption and elimination is confined to the first com-
partment. This assumption is physiologically consistent since most drugs are 
absorbed or infused into the blood stream and most drug elimination occurs 
from the blood stream. Since theophylline is not biotransformed in the sur-
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rounding tissues, no elimination or input path is attached to the second com-
partment. 
Drug removal is represented by two elimination routes. One path rep-
resents elimination by the kidneys and the other path represents the elimina-
tion or biotransformation of theophylline that occurs in the liver. Although 
most theophylline elimination occurs in the liver, the kidneys also eliminate 
active drug and are important in drug removal during the early stages of life. 
Therefore, parameter lumping is not used to combine these two elimination 
routes, because it removes physical reality from the model. 
The diffusion processes that occur between the compartments are rep-
resented by two transport paths. The importance of using two paths for theo-
phylline kinetics is marginal due to the apparent reversibility of the transport. 
However, the consideration of two paths makes it possible to demonstrate the 
kinetic impact of rate-limited transport and directional preference. For exam-
ple, this model can be used to demonstrate the kinetic behavior that results 
when drug molecules develop an increased affinity for tissue proteins. 
Absorption and Infusion Kinetics 
The absorption and infusion kinetics of the system are not directly repre-
sented in the model. Instead, the drug input into the system is represented by 
an infusion or absorption path into the system. This input path has units 
that are expressed as: 
Infusion Path Units = Mass of Drug/Unit Time (3.2) 
The actual input rate to the system is dependent upon the dosage form, the 
method of delivery, and other variables. These absorption rate kinetics are 
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handled in a separate system representation that passes the drug input rate as 
a parameter to the the theophylline kinetics model. This is a modular ap-
proach which facilitates modeling different drug administration methods. 
Transport Kinetics 
Transportation between the two compartments is represented by two 
transport routes. These routes consist of a path from the plasma compart-
ment to the surrounding tissues and a return path from the tissues to the 
plasma compartment. The transport across these paths is modeled as a facili-
tated diffusion process. The rate of diffusion is based upon the difference in 
the unbound concentrations: 
Rate of Diffusion = (Cui - Cu2) • K (3.3) 
Elimination Kinetics 
Drug elimination is represented here as occurring in two organs - the 
liver and the kidney. The actual elimination of theophylline from these or-
gans is assumed to be dependent on the unbound concentrations of the drug. 
This is a logical modeling conclusion, since the extraction ratio for theo-
phylline is very low (see Chapter 2). 
The rate of elimination from the liver is given by: 
Liver Elimination = Cui • Ki (3.4) 
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The rate of elimination from the kidney is represented as: 
Kidney Elimination = Cui • Kk (3.5) 
Typical units for the unbound concentration (Cu) and the elimination pro-
portionality value (K) are mg/liter and liters/hour or |ig/ml and ml/rnin re-
spectively. Since the transport is a function of the unbound concentrations, 
the proportionality values are actually the unbound clearance. Care must be 
taken to avoid confusing this with the total clearance which is based on the 
total concentration. 
Saturation of the elimination paths which can occur at high drug con-
centrations and is represented by a separate computer algorithm. This algo-
rithm is based on the Michaelis-Menton equation and expresses the rate of 
drug elimination in terms of the total drug concentration (C), the maximum 
elimination rate (Vm ax)/ the half maximal elimination rate (Km), and the 
rate of total clearance (CL). In this equation, the rate of elimination is repre-
sented as occurring from two paths, one saturable and one first-order. The 
expression is: 
Rate of Elimination = Vmax x C/(Km + C) + CL x C (3.6) 
At low concentrations relative to Km, the elimination rate is approximately 
first order, and at higher concentrations the elimination rate behaves non-
linearly and approaches a new rate of: 
Rate of Elimination = Km + CL x C (3.7) 
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In the saturation algorithm, equation 5.1 is re-expressed in terms of the total 
clearance as: 
Total Clearance = V m a x / (Km + C) + First Order Clearance (3.8) 
During saturation kinetics, the algorithm computes the value of elimination 
from equation 5.3 and modifies the current values of Kk and Kl in the theo-
phylline kinetics model. 
Kinetic Model Derivation 
A total mass balance relation for the system that is given by: 
m l = u l + rri2i - mi2 - rrtL - mK (3.9) 
rri2 = rhi2 - rfi2i (3.10) 
The terms for rh are the mass flow (mg/h) of drug into and out of the two 
compartments . The u l term is the drug input to the system. To be useful for 
simulation and control, these expressions must be expressed in terms of drug 
concentrations. Recall that the unbound concentrations in the compartments 
can be expressed as Cu = C xfu. 
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Because drug transport phenomena is based on the unbound drug concentra-
tions, the following relations result: 
m l = ill + (C2 • fu2 - CI -ful) K21 - (CI • ful - C2 fu2) -K12 , 
(3.11) 
- (CI • ful) • KL - (CI ful) • KK 
m2 = (CI -ful - C2 -fu2) • K12 - (C2 • fu2 - CI • ful) • K21 (3.12) 
In equations 3.8 and 3.9, the concentration (C) is the total plasma drug concen-
tration. When the time variance in the volumes of distribution is small: 
m = £- (3.13) 
V 
Using (3.10) to rewrite (3.8) and (3.9) yields: 
CI = ̂  + (C2 • fu2 - CI ful) - ^ 1 - (CI • ful - C2 fu2) -&1^ 
V 1 V 1 „ V 1 (3.14) 
- (CI • ful) • ^ L - (CI ful) • ^ 
VI VI 
C2 = (CI -ful - C2 -fu2) • ^12. . (C2 • fu2 - CI • ful) • £ 2 1 (3.15) 
V2 V2 
Equations 3.11 and 3.12 are the two coupled, linear, ordinary differential equa-
tions used to represent the kinetic behavior of theophylline. The state-space 
representation for these equations can be developed by introducing the fol-
lowing new expressions for the rate of transport between compartments and 
for the rate of drug elimination. 
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The rate of transport is expressed as: 
K = (K12 + K21) (3.16) 
The value for the combined transport rate is dependent on the relative con-
centrations in the two compartments. This concentration dependance is ex-
pressed as: 
K = K12 (C1>C2) 
K = K21 (C2>C1) 
(3.17) 
Equation 3.14 is necessary for modeling the directional nature of the trans-
port between the two compartments. The combined expression for the rate of 
drug elimination is: 
Kel = (KL + KK) (3.18) 
After simplifying Equations (3.11) and (3.12), the following state-space repre-

















The methods used to solve these differential equations within the software 
program are briefly discussed in chapter 5. 
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CHAPTER IV 
FUZZY LOGIC MODELING AND INTELLIGENT CONTROL 
This chapter discusses fuzzy logic and intelligent control. Particular emphasis 
is given to explaining the structure of fuzzy associative memory controllers 
(FAM). After some introductory material, two control algorithms which in-
corporate information about the patient with intelligence rules are devel-
oped. The first algorithm is a FAM controller and the second algorithm is a 
combination of discrete sliding mode control with fuzzy logic rules for sam-
pling rate and error detection. 
Fuzzy Logic Modeling 
Fuzzy logic modeling is based on the concept of the fuzzy set. It was 
initially developed by Lofti Zadeh in 1965 [46]. Fuzzy logic expresses truth as 
a matter of degree. To illustrate this concept, Figure 4.1 shows a fuzzy set rep-
resentation of the control action that could be used to apply medium brake 
pressure in an automobile. In this figure, the membership function relates 
numerical values of the control variable to the concept of medium brake 
pressure. This particular membership function classifies a medium brake 
pressure as having a value of 5. Other values of the control effort are consid-
ered to be medium to a degree that is determined by the membership func-
tion. This ability to associate numerical values to qualitative control concepts, 
39 
such as medium brake pressure, simplifies the representation of control rules 
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Figure 4.1 Fuzzy Set Representation for Applying Medium Brake Pressure 
Fuzzy logic models and FAM controllers associate information and 
knowledge through the use of rules that are expressed in the form of "IF-
THEN" relationships. Although this feature is shared by conventional rule-
base structures, fuzzy logic rules apply in multiple situations with differing 
degrees of output response. This increased range of application greatly re-
duces the total number of rules required. 
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Consider the following "IF-THEN" rule: 
IF Control Error is Small Negative 
AND Velocity is Large Positive 
THEN Brakes Medium. 
In a normal "IF-THEN" rule, the application of the rule is usually a boolean 
function of the input variables (The rule is active or inactive). When fuzzy 
sets are used within this framework, the rule functions when the variable for 
control error and the variable for velocity are either completely or partially 
matched. The resulting output for the application of the brakes in the auto-
mobile is a function of the degree to which the conditions for the variables 
are matched. 
When expressing a fuzzy logic variable, the set of all possible values for 
the variable (universe of discourse) is represented by several overlapping 
fuzzy sets. Returning to the example for automobile brakes, the library of 
fuzzy sets for the variable control error is shown in Figure 4.2. Here, the vari-
able is represented by seven different fuzzy sets. These sets are named large 
negative (LN), medium negative (MN), small negative (SN), zero (ZE), small 
positive (SP), medium positive (MP), and large positive (LP). In developing 
these membership functions, a rule of thumb is to require the adjacent fuzzy-
set values overlap approximately 25 percent [47]. Adopting this rule, values 
for the variable control error are members of at least one of the fuzzy sets and, 
in some regions, are members of two fuzzy sets. This dual membership is 
one of the conditions that causes fuzzy control rules to activate in parallel. If 
a value for one of the control variables has membership in two or more fuzzy 
sets, multiple rules will be activated by the single numerical value of the con-
trol variable. The activation of control rules in parallel is important because 
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it reduces discontinuities that would otherwise exist in switching from one 
rule to another. The application of multiple rules also increases the robust-
ness of the fuzzy rule-base, because errors in a single rule are less likely to cor-
rupt the overall output behavior. 
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Figure 4.2 Fuzzy Set Representation for the Values of Control Error 
The determination of a fuzzy control effort from the IF-THEN rule is a 
multi-step process that requires the manipulation of fuzzy sets. First, the de-
grees of membership for the values of control error and velocity to the fuzzy 
sets negative small and positive large must be determined. After determin-
ing the degree of membership, its value is used to scale the output fuzzy set 
medium that is used for brake control. In rules that have the AND conjunc-
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tion, the smallest degree of belief is used to scale the output fuzzy set. This re-
flects the fact that the variable with the smallest level of agreement should be 
the limiting factor in determining the control effort. Likewise, rules with the 
OR conjunction use the highest degree of belief to scale the output fuzzy set. 
A fuzzy control system activates multiple rules simultaneously to de-
termine the output variable. Each of the scaled fuzzy sets that were calculated 
from the degree of memberships are added together. The output variable that 
results is a new fuzzy set that is a superimposed combination of the fuzzy set 
outputs from each of the individual control rules. The resulting fuzzy set ap-
pears similar to the representation shown in Figure 4.3. 
Although the fuzzy output is useful, most control action requires a sin-
gle numerical value. To obtain a single value from the fuzzy set, a process 
called defuzzification is used. Here, the technique of defuzzification that is 
used is the centroid method. In this method, the output value corresponds to 
the center of gravity for the output fuzzy sets. 
When defining a fuzzy logic rule-base, a significant amount of effort 
must be devoted to defining the fuzzy sets and selecting the membership 
functions that are used within the rule-base structure. A variety of different 
techniques for developing fuzzy sets have been used over the years. At pre-
sent, there is no standardized approach. The technique that is used to de-
velop the algorithms in this thesis is based on the judgement of experienced 
personnel. This is useful because practitioner rules for drug dosing are often 
based on intuition. The fuzzy sets, rules, and membership functions that are 
developed using this approach represent a subjective view of the problem 
based upon past experience. 
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Control Effort Value 
Figure 4.3 Fuzzy Set Representation for the Values of Control Error 
Intelligence-Based Control Algorithms 
The following chapter introduces the application of intelligence-based 
control for drug administration. The purpose for developing these algo-
rithms is to illustrate their ability to increase control performance at slow 
sampling rates (several hours) by using information about the patient. 
Improvements are achieved by using additional information such as knowl-
edge about the patient and drug kinetics to supplement standard feedback 
data. One of the purposes for using this additional information is to modify 
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the controller response to the type of patient being treated and to reduce the 
effects of sampling errors. 
The controllers adjust their control characteristics based on several dif-
ferent types of data. The data considered here includes the style of therapy, 
the presence of interacting drugs or diseases, and the past performance of the 
controller. Specific data, such as the exact kinetic parameters, are not required 
by the algorithms. This important because exact information about the pa-
tient parameters is difficult to obtain. 
The initial infusion rate is determined by from population informa-
tion. After a delay of 3 times the half-life, the controllers actively adjust the 
drug concentrations. This initial infusion approach is adopted to create a 
faster control response and to reduce the number of samples during the first 
hours of drug administration. 
Two different knowledge-based algorithms are presented. The first 
uses fuzzy logic and FAM control techniques exclusively. The second im-
plements a combination of discrete sliding mode control and fuzzy logic. 
Simulation results for the controllers are presented in chapter 6. 
FAM Controller 
The FAM controller uses fuzzy logic rules to adjust the infusion and 
sampling rates of the administered drug. This controller is similar to the 
knowledge-based controller that was described by Linkens and Mahfouf [48] 
for muscle relaxant anaesthesia. A block diagram representation for this con-
troller is provided below in Figure 4.4. The left side of the diagram shows the 
input variables into the modules of the controller. The right side shows the 
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Figure 4.4 Block Diagram Representation of the FAM Controller 
The controller is composed of three primary algorithms. The control 
module uses feedback information and other data to make alterations in the 
drug infusion rate. The sample rate module uses data to modify the sampling 
rate of the controller, and the sample evaluation module uses information 
about past errors to help detect possible sensor errors. 
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Control Variables. Several different types of variables are used by the 
FAM controller to determine its output. These variables can be categorized 
into three groups - feedback variables, patient information variables, and con-
trol parameter variables. 
Feedback variables are used by the controller to calculate adjustments 
to the infusion rate and to detect sensor errors. These variables include the 
concentration error, the proximity to the recommended infusion, the maxi-
mum infusion rate, and the kinetic scaling factor. 
The concentration error variable is the difference between the desired 
and the actual concentrations. The proximity to the recommended infusion 
is based on the difference between the current infusion rate and the recom-
mended infusion rate which is calculated from population averages. The 
maximum infusion rate variable is in units of (mg/hr) and is used as a limit 
on the control output. The kinetic scaling factor is based on the relative clear-
ance of the system and is defined as: 
Kinetic Scaling Factor = Est. Clearance ( 4 A ) 
Reference Clearance 
The estimated clearance in (4.1) is based on the age, weight, and population 
base of the patient; the reference clearance is the value that was used in de-
veloping the control algorithm. 
The scaling factor helps to maintain similar control convergence for 
different patients. A variable for the change in concentration error is not 
used because of the slow sampling rates that are used (2 to 3 times the half-life 
of the system). 
The patient information parameters affect the sampling and evalua-
tion of plasma concentrations. The variables are boolean and indicate the 
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presence of liver disease and the concurrent administration of either cimeti-
dine or erythromycin. 
The control parameter variables affect the control performance charac-
teristics. These parameters are the sample data memory and the style of ther-
apy. The sample data memory can be one of three values - long, medium, or 
short. A higher value for the memory variable increases the weighting (w) 
on the absolute value of the concentration error and affects the following 
equation (the forgetfulness formula): 
|CE3| • (w)+|CE2| • (w+0.25)+|CEl| 
Average Error = •— (4.2) 
6 (1.25+ 2w) 
The variable for the style of therapy modifies the control action of the fuzzy 
logic rule-base. The variable can assume values that are between 0 and 10 
and is used to adjust the behavior of the controller. Values for the variable 
correspond to conservative (0), moderate (5), or aggressive treatment styles 
(10). Depending on value of the variable, the controller will implement 
more or less aggressive control actions. Here, a value of 3, will implement a 
style of therapy that is a combination of the conservative and moderate 
treatment styles. 
Infusion Control Algorithm - Structure and Principals. The control ac-
tion of the FAM controller is determined by a group of IF-THEN rules. Two 
modules of control rules determine the overall control system strategy. The 
first group is used to modifying the infusion rate. The second group is used 
to adjust the sample rate. 
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The general philosophy behind the control rules for modifying the in-
fusion rate is to increase the amount of drug infusion if the drug concentra-
tions are to low. The proximity to the recommended infusion rate and the 
style of therapy are used as references for choosing the size of the dosage 
change. The variable for the maximum infusion rate prevents the controller 
from infusing levels of drug that are higher than those set by the operator of 
the controller. The rules for this part of the algorithm are structured in the 
following fashion: 
IF Control Error is Positive Medium 
AND Recommended Proximity is Close 
AND Therapy Style is Conservat ive 
THEN Change in Infusion is Positive Small 
The module for sample rate adjustments uses information such as the 
concentration error and presence of disease states. To adjust the sampling rate 
In conditions of large concentration error or drug interactions, smaller sam-
pling times are used. When the system is near the desired concentration and 
is not likely to be susceptible to changes from drug interactions and other fac-
tors, a longer sampling time is used. The rules for this part of the controller 
are structured in the following format: 
IF Control Error is Zero 
AND Drug Interaction is Low 
THEN Sample Rate is S low 
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The module for sample evaluation uses the value of the current con-
centration error, the average concentration error from (4.2), and the presence 
of diseases or drug interactions to evaluate the current sampled data. In con-
ditions of large concentration error, the module compares the current sample 
to prior samples. If the previous samples were near the desired concentration 
and interactions are unlikely, the module will reduce changes in the infusion 
by adjusting the scaling factor. A second sample is taken within 4 hours to 
validate or nullify the effects of the previous sample. The rules for this part 
of the controller are structured in the following format: 
IF New Concentration Error is Negative Big 
AND Average Concentration Error is Low 
AND Drug Interaction is Low 
THEN Scale is Low 
Fuzzy Logic and Discrete Sliding Mode Control 
The second controller uses fuzzy logic rules to adjust the infusion and 
sampling rates of the administered drug and to evaluate the sampled data. 
The actual administration rates are determined by using discrete sliding mode 
control [49]. The parameter bounds for the sliding mode controller are auto-
matically selected based on population information for the patient groups 
that have been modeled in the system. The fuzzy modules for this controller 
are similar to those used with the FAM controller. A block diagram represen-
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The software that accompanies this thesis functions as a teaching tool 
for pharmacokinetics and serves as a platform for experimenting with control 
algorithms for drug administration. The software has three primary modes 
of operation. These modes are used for simulating drug kinetics, for teaching 
aspects of drug administration, and for investigating the performance of con-
trol algorithms. In this chapter, information is provided to familiarize the 
user with the general features of the software and to briefly explain some of 
the program algorithms. 
Software Development 
The current version of the software was developed using the C pro-
gramming language and is designed to run on Macintosh color computers. 
The Macintosh computer was chosen because of its graphics capabilities and 
ease of use. Because the software implements special features of the Macin-
tosh, the program code is not directly portable to other machines running 
ANSI C. However, the program algorithms which are used for control, simu-
lation, parameter variation, and other features are transferable. 
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Screen Layout 
The graphical layout for the program is shown in Figure 5.1. As shown 
here, the program screen displays a two compartment model (item#l) in 
which the first compartment represents the plasma volume and the second 
compartment represents the tissue volume. The numerical displays (item#2) 
give the current parameter values for the transport coefficients, infusion rate, 
volumes of distribution, and elimination rate. The arrow keys that are lo-
cated to the right and left of the parameter value display boxes are for chang-
ing the current parameter values up or down. It should be noted that the 
liver and kidney values are expressed in terms of the unbound concentra-
tions (see Chapter 3). The upper right corner of the program screen has a se-
lectable, 3 parameter graphics display (item #3) which plots parameter value 
as a function of the time. The buttons located below the graphics display, run, 
pause, and reset the computer program. A clock (item #4) indicates the cur-
rent time of the simulation in days and hours. Beneath the graphics display, 
a small outlined region is reserved for displaying text about the patient or for 
explaining concepts when the program is in the teaching mode. Arrow keys 
located to the right and left of the box are for stepping through the text and 
example simulations. The lower right portion of the screen has controls for 
adjusting the protein binding (item #5) in the two compartments and is ex-
pressed in terms of the percent of unbound drug. 
Software Menus 
Program features are selected through the use of pull down menus. A 
total of four main menus are implemented in the software. These are the sys-
tem setup, simulation mode, study mode, and control mode menus, (see Fig-
ure 5.1) Listed inside of each pull down menu is a list of options. These op-
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tions reference a dialog window that is used for inputing information into 
the program. When the user selects a menu item, the referenced window ap-
pears on the computer screen and is available for use. A brief description of 
the four main menus follows. 
t w File Edit System Setup Simulation Mode Study Mode Control Mode <& 
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Figure 5.1 Software Screen Layout and Graphics Display 
System Setup Menu 
The system setup menu allows the user to select parameters that affect 
software plotting, graphing, operation mode, and data storage features. The 
purpose of this menu is to allow the user to customize the software for illus-
trating selected topics. For example, the submenu compartment level refer-
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ences a dialog window that allows the user to modify the compartmental dis-
play. The user can select to display the drug levels in terms of either the un-
bound or total drug concentrations. This flexibility can be used to display the 
effects of protein binding on total drug concentration or for demonstrating 
that the drug distribution model is at equilibrium when the unbound concen-
trations are identical. 
Simulation Mode Menu 
The simulation mode menu has five submenus that affect the behav-
ior of the program when it is operating in the simulation mode. These op-
tions allow the user to alter initial conditions, change the reference data, ad-
just infusion or absorption rates, select the method of delivery, and add satu-
ration kinetics. The purpose of this menu is to permit the user to simulate 
and study the effects of various changes in the pharmacokinetic model devel-
oped in chapter 3. 
Four different methods of drug administration are available to the user 
in the simulation mode of the software. These are bolus dose infusion, rapid 
release capsules, slow release capsules, and continuous infusion. The bio-
vailability for the capsules is assumed to be 95% and the biovailability for the 
continuous infusion is assumed to be 100%. 
Study Mode Menu 
The study mode menu allows the user to select a topic in pharmacoki-
netics and receive instruction and a short demonstration on the concept cho-
sen. The topics available for instruction include drug interactions, dose 
dumping, and capsule release rates. 
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Dose Dumping Tutorial. Dose Dumping is a phenomenon character-
ized by the unexpected and sudden release of theophylline from oral capsules. 
It is usually observed with the use of slow release formulations and quite fre-
quently is associated with taking the tablet with food. The following figure 
[50] demonstrates the effects of dose dumping. 
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Figure 2.4 Theophylline Dose Dumping of a Slow Release Product. 
Drug Interaction Tutorial. The drug interaction example illustrates the 
effect of a concurrently administered drug on theophylline clearance and 
steady state drug concentrations. A drug interaction occurs if the pharma-
cokinetics or pharmacodynamics of one drug is altered by the concurrent ad-
ministration of a second drug. The noticeable effects of a drug interaction are 
frequently delayed for hours or days after starting the concurrent administra-
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tion. The concurrently administered drug used in this lesson causes a reduc-
tion in theophylline clearance and increases the steady-state concentrations. 
Release Rate Tutorial. When choosing a form of theophylline administra-
tion, it is important to consider the characteristics of the patient that is being 
treated. In this lesson, the properties of slow and fast release capsules are 
compared. The simulations show that the age and characteristics of the pa-
tient affect the selection of administration forms. Patients that have high 
clearances and shorter half-lives will have larger fluctuations with the fast re-
lease product. As a result, slower release products are shown to yield more 
desirable concentration responses in these patients. 
Control Mode Menu 
The control mode menu is designed to allow the user to adjust param-
eters necessary to experiment with drug infusion control techniques. Menus 
permit the user to select and set options on each of the three control tech-
niques presented. The user can change sampling rates, adjust patient parame-
ters, and modify control performance criteria. Patient input information and 
parameter variation options are also available. These allow the experimenter 
to create a realistic patient and add uncertainty and error to the system as a 
way to evaluate controller performance. 
Software Algorithms 
The software implements a number of features through specialized al-
gorithms. These algorithms include program code for altering patient pa-
rameters, for determining drug concentrations from reference models, and 
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for controlling drug levels. Information and a brief explanation about some 
of these algorithms is given in the following paragraphs. 
Reference Model Algorithm 
The reference model algorithm for the patient body system is based 
upon the equations that were derived in Chapter 3. These differential equa-
tions express the kinetic behavior of drugs in a patient and are time variant. 
To solve the model equations, two approaches were compared. These 
were a fourth order Runge-Kutta algorithm and a time-invarient exact solu-
tion that was determined using Laplace transform techniques. The stepsize 
for the Runge-Kutta algorithm was adaptively controlled in order to main-
tain an accuracy of 1.0e-6. 
Two methods of parameter selection were tried for the time-invarient 
solution. The first method used the current parameter value during the inte-
gration. The second used the average of the current and previous value dur-
ing the integration (midpoint method). In the simulation, the period of in-
tegration for the time-invarient case was 15 minutes (relative simulation 
time). This effectively discretizes parameter changes into several small steps, 
because most parameter changes occur slowly in the body over a period of 
several hours. 
Three time variations in the level of drug clearance, one linear and 
two nonlinear, were considered. The Runge-Kutta algorithm with error con-
trol was stable and accurate, but used more time to calculate the next concen-
tration. In contrast, the exact solution was nearly twice as fast as the Runge-
Kutta solution, but sacrificed accuracy. Using the Runge-Kutta solutions as a 
reference, the two time-invarient solutions were compared. The average per-
centage difference for the algorithm using the current parameter value dur-
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ing integration was 0.1677%. The percent difference for the algorithm using 
average parameter values was 0.0055% and is 30 times more accurate than the 
current value algorithm 
Because of its speed and accuracy, the time-invarient method with av-
erage parameter values is implemented in the software. This algorithm uses 
a static variable structure to maintain information about previous parameter 
values. During simulation, new parameter values are averaged with old 
ones and substituted into the equations for determining the concentration. 
Control Algorithms 
Three different control algorithms are used by the software. They are a dis-
crete sliding mode control, fuzzy logic control, and a control algorithm which 
combines fuzzy logic with discrete sliding mode control. 
Discrete Sliding Mode Control. The sliding mode control algorithm is 
an implementation of the work by Godwin. [51] The algorithm uses bound-
ing of the parameters and achieves control stability in the presence of uncer-
tainty. The selection of the parameter bounds is a function of information 
about the patient. Two options exist for parameter selection. These are au-
tomatic and manual mode. In the manual mode, control parameters are se-
lected by the software user. In the automatic mode, population information 
regarding typical values is used to set the parameter bounds. 
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Fuzzy Logic Control. The fuzzy logic control algorithm is based upon a 
a set of fuzzy logic rules for basic system control. The rule base uses rules of 
the following form: 
IF Concentration is Slightly High 
AND Change in Concentration is Positive 
AND Change in Concentration is Small 
THEN Reduction in Infusion is Medium. 
Fuzzy Logic Decision Rules and Discrete Sliding Mode Control. The fi-
nal control algorithm combines discrete sliding mode control with fuzzy logic 
decision rules. The fuzzy logic rules in this algorithm use a basic level of clin-
ical judgement to evaluate sampled data feedback and make determinations 
about the infusion rate. In general, the rules are oriented to try and make the 
overall application stability of the discrete sliding mode control algorithm 
higher. The discrete sliding mode control algorithm is used to make recom-
mendations on the next infusion rate because of its stability and ability to 
function in the presence of parameter uncertainty. 
Patient Parameter Algorithms 
The parameters for the patient can be varied in several different ways. The 
purpose of this variation is to add uncertainty and time changes which ap-
proximate those that occur in real patients. By doing this, it is possible to cre-
ate realistic situations that test control effectiveness. The types of variations 
and uncertainty that are available to the user include sampling error, steady 
state parameter error, parametric variation, and saturation kinetics. The 




















Figure 5.2 Block Diagram Representation of Patient Parameter Algorithms 
Sampling Error. The algorithm for sampling error uses an algorithm 
from [52] to generate sampling errors. The normal distributions that are used 
have a mean of zero and a standard deviation that is specified by the user. 
Two independent distributions are implemented. The first simulates the 
sample errors which occur in the sampling process, and the second simulates 
the uncertainty that is a result of laboratory assay. In addition, a third random 
number generator is used to approximate the affects of a defective sensor. 
Steady State Parameter Error. The algorithm for steady state parameter 
error allows the user to selectively offset the patient parameters from the 
population norms. This allows the software user to test the controller sensi-
tivity to values that are higher or lower than expected. Two parameters, 
clearance and total volume, can be varied. These particular parameters were 
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selected because they represent the areas of greatest parameter variability and 
uncertainty in theophylline patients. 
Parameter Variation. In addition to steady state error, additional 
uncertainty can be added in the form of time variations to the patient param-
eters. These variations include circadian clearance, and transitions between 
sick and normal patient parameter values. 
The algorithm for circadian clearance is used to add a cyclical variation 
in the clearance values and is expressed by the following relationship: 
Clearance = CI x (l+(Var%/100) x sin(27t/P) x time)) (5.1) 
The user inputs the percentage of variation (Var%) and the period of the 
variation (P) to create a desirable parameter variation. 
The Transition algorithm is a parameter variation algorithm that alters 
patient parameters between two extremes of physical conditions, sick and 
normal. The algorithm linearly adjusts patient parameters between each of 
the two extremes, and two types of variations can be chosen. The user can se-
lect to have the patient transition from normal to sick or from sick to normal. 
The user inputs the delay time before starting the time over which the transi-
tion should occur. The final values of the parameters are determined by the 




Simulations on the control techniques that were explained and 
developed in chapter 4 are presented in the following chapter. The simula-
tions were performed in order to evaluate the effectiveness of each controller. 
The performance of the controller is a function of its ability to maintain the 
proper drug concentration levels while parameter variations and sampling 
error are occurring in the system. 
Three different control algorithms are compared. They are discrete 
sliding mode control, fuzzy logic control, and intelligent sliding mode control 
(a combination of patient information and fuzzy rules with sliding mode con-
trol). The model variation, sampling error, and other simulation options 
that are used for testing the control algorithms are components of the soft-
ware program and are selected through the use of menus such as the one 
shown in Figure 6.1. 
In the first simulation, the effects of sampling error are considered. 
Figure 6.2 shows the affect of sampling errors on the control response of the 
discrete sliding mode controller. Here, sensor errors cause a serious alteration 
in the drug infusion rate and control performance. This alteration in control 
performance is indicated by the large fluctuation in the plasma drug concen-
tration levels. 
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Figure 6.3 displays the simulation results for the intelligent sliding 
mode controller. In this controller, a fuzzy logic routine is used to evaluate 
the sampled data. The application of this evaluation algorithm reduces the 
sensitivity to sample errors. 
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Figure 6.2 Controller Response without a Sample Evaluation Algorithm 
Figure 6.4 demonstrates the degradation in controller performance that 
occurs as a result of selecting the control variables (parameter bounds, rise 
time, etc.) for the discrete sliding mode control algorithm incorrectly. In this 
example, the controller performance is reduced and the response is very slow 
This controller fails to achieve the desired drug concentrations prior to the 
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Figure 6.3 Controller Response with a Sample Evaluation Algorithm 
In contrast, Figure 6.5, shows the performance of the same control algorithm 
after information about the patients age, weight, and condition have been 
used to determine the control parameters. The result is an improvement in 
the rate of convergence to the desired drug concentration. This improvement 
illustrates the importance of patient information to optimal control perfor-
mance. 
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Time of Simulation (h) 
Figure 6.4 Control Performance without Proper Parameter Selection 
Figure 6.6 is a plot of the control response and infusion rate changes 
that occur when the fuzzy logic controller is used with an algorithm to auto-
matically adjust the sample rates. Here, the controller uses a smaller sam-
pling rate during the initial stages of drug treatment. After the first few 
hours, the controller increases the delay between samples. The capability to 
dynamically adjust sample rates is important because drug samples are expen-
sive and labor intensive to perform. 
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Figure 6.5 Control Performance with Proper Parameter Selection 
The next group of figures are from simulations in which the con-
trollers are used to administer theophylline to a simulated patient case. The 
test is based on the pharmacokinetic parameters of a pediatric patient that is 8 
years old and has a weight of 25 Kg. The patient is assumed to be concurrently 
taking erythromycin (an interacting drug). The desired steady-state plasma 
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Figure 6.6 Sample Rate Adjustment in the Fuzzy Logic Controller 
Errors in the laboratory measurement of theophylline concentrations 
in the laboratory are assumed to have a standard deviation of 0.3. The collec-
tion standard deviation is assumed to be 0.8. The theophylline sensor is se-
lected to be detective (yields frequent and large sample errors). The steady 
state parameter errors are set to be at 90% of the sick and normal patient val-
ues respectively. Circadian variation in the clearance is set to occur at a pe-
riod of 28 hours with a percentage variation of +- 20%. The transition be-
tween the normal and sick patient parameters is set to be delayed by 30 hours 
after the initiation of drug therapy and occurs over a time period of 12 hours 
(similar to an actual drug interaction). 
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The performance results of the discrete sliding mode controller with a 
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Figure 6.7 Discrete Sliding Controller (Sample Rate = 6 hours) 
The large decrease in concentrations for the discrete sliding mode controller is 
the result of errors from bad sample points. The next three figures are simu-
lations for the fuzzy logic controller response to the test case. Figure 6.8 is a 
simulation for the control response that occurs when the fuzzy logic con-
troller is set to administer drug dosing conservatively. 
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Figure 6.8 Fuzzy Logic Controller (Conservative Treatment Style) 
The response time for the fuzzy logic controller is slower while operating 
with this style of therapy; however, the likelihood of patient toxicity is also 
reduced. 
Figure 6.9 shows the simulation results for the controller while func-
tioning with a moderate style of drug treatment, and Figure 6.10 corresponds 
to an aggressive style of drug treatment. These figures show that the more 
aggressive styles of drug treatment increase the peak drug concentration 
levels. 
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Figure 6.10 Fuzzy Logic Controller (Aggressive Treatment Style) 
Figure 6.11 on the following page shows the simulation results for the intel-
ligent discrete sliding mode controller. This controller achieves the desired 
concentration rapidly and maintains reasonable peak concentration values 
that are below 20 [ig/ml. 
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Figure 6.11 Intelligent Discrete Sliding Mode Controller 
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CHAPTER VII 
CONCLUSION AND RECOMMENDATIONS 
This thesis has focused on the development of a computer software 
teaching tool for theophylline kinetics and on the use of modern control 
techniques for drug administration. Special emphasis was given to 
developing an accurate model representation of theophylline kinetics. This 
model is based on the transport of the unbound portion of the drug and 
acknowledges that it is the unbound drug that is therapeutically important. 
The simulation results from the drug administration controllers have 
demonstrated the importance of information such as disease states and drug 
interactions on improving the accuracy of drug administration techniques. 
The application of fuzzy logic has been shown to yield improved controller 
response, particularly in the case of large sensor errors which undermine 
traditional techniques. 
Although the controllers that were developed implement some 
knowledge about the patient, considerably more information should be 
incorporated into future algorithms. For example, information about the 
severity of illness and temporal (time) relationships could also prove to be 
useful in improving controller response. 
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